Cavrotolimod targets PD-1 inhibitor resistance
Douglas Laux, MD, with John Jesitus Patients with Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC) refractory to programmed cell death protein 1 (PD-1) inhibition may one day have a silver bullet that renders these cancers susceptible to PD-1 checkpoint inhibitors. This is one of the goals for the clinical development of cavrotolimod […]